CG Oncology, Inc. Common stock
CG Oncology, Inc. Common stock (CGON) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CGON · as of Mar 31, 2025
Ownership Breakdown
144
Institutional Holders
▲ 1 vs Q4
$1.74B
Total Inst. Value
▼ $160.17M vs Q4
88.20M
Shares Outstanding
freeFloat 74.63%
70.76M
13F Shares Held
▲ 4.54M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CGON largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
DECHENG CAPITAL LLC biological products, (no diagnostic substances) | 6.37M | 8.36% | 8.36% | $156.04B | May 8, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 5.84M | 7.66% | 7.66% | $142.93B | May 9, 2025 | ▼ 24.8K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.36M | 5.72% | 5.72% | $106.66B | May 2, 2025 | ▲ 293.9K |
TCG CROSSOVER MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.67M | 4.82% | 4.82% | $89.88B | May 14, 2025 | — held |
BRAIDWELL LP biological products, (no diagnostic substances) | 3.28M | 4.31% | 4.31% | $80.41B | May 15, 2025 | — held |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 2.61M | 3.43% | 3.43% | $63.96B | May 15, 2025 | ▲ 92.0K |
FMR LLC biological products, (no diagnostic substances) | 2.55M | 3.34% | 3.34% | $62.33B | May 12, 2025 | ▲ 111.5K |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 2.47M | 3.24% | 3.24% | $60.54B | May 15, 2025 | ▲ 1.04M |
MARSHALL WACE, LLP biological products, (no diagnostic substances) | 2.42M | 3.17% | 3.17% | $59.23B | May 15, 2025 | ▲ 960.4K |
FORESITE CAPITAL MANAGEMENT VI LLC biological products, (no diagnostic substances) | 2.22M | 2.92% | 2.92% | $54.40B | May 15, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
27
Increased
+6.47M shares3
New Positions
first time holders10
Decreased
−535.5K shares0
Sold Out
fully exitedNet shares change (top 50)
+5.93M
+6.47M / −535.5K
Net new holders
+20
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CGON insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
4
Sell transactions
3.25
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Liu Brian Guan-Chyun director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Tong Victor Edward Jr director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Mulay James director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
POST LEONARD E director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Rossi Christina director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
POST LEONARD E director | Jun 4, 2026 | Sale | 1,000 | $54.50 | $54.5K | 0 | Form 4 ↗ |
Graf Susan E director | Jun 4, 2026 | Award | 9,354 | $56.09 | $524.7K | 9.4K | Form 4 ↗ |
Mulay James director | Apr 17, 2026 | Sale | 15,600 | $73.01 | $1.14M | 0 | Form 4 ↗ |
Bellete Ambaw President and COO | Apr 15, 2026 | Award | 107,508 | $67.68 | $7.28M | 107.5K | Form 4 ↗ |
Kasturi Vijay Chief Medical Officer | Apr 15, 2026 | Award | 79,216 | $67.68 | $5.36M | 79.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
CG Oncology, Inc. Common stock (CGON) is primarily owned by institutional investors, who hold approximately 80.2% of total shares outstanding. Company insiders own approximately 25.37%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of CG Oncology, Inc. Common stock is DECHENG CAPITAL LLC, holding approximately 6.37 million shares — equal to 8.36% of outstanding shares — as of March 31, 2025.
A total of 144 institutional investors currently hold CGON stock, with a combined institutional value of approximately $1.74 billion as of the most recent 13F filing period.
Frequently asked questions
CGON ownershipCG Oncology, Inc. Common stock (CGON) is primarily owned by institutional investors, who hold approximately 80.2% of shares. The largest shareholder is DECHENG CAPITAL LLC with a 8.36% stake. Company insiders hold 25.37%. Data sourced from SEC Form 13F as of March 31, 2025.